Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202522350

Mycoplasma Pneumonia: Nursing Assessment, Evidence-Based Management, and Infection Prevention Strategies

Maha Ghdaif Alanazi [(1)] , Mashail Salem Almuzail [(1)] , Anwar Ghazwan Salim Al-Mahdi [(2)] , Amnah Ibrahim Ageeli [(3)] , Salwa Taher Aldalwi [(4)] , Nouf Mawash Alenezy [(5)] , Awatef Salem Saad [(6)] , Tahani Mohammed Al Hwiti [(7)] , Norah Mulfi Nuwaydis Alrashdi [(8)] , Abeer Nazal Alhazmi [(9)] , Sara Abdullatif Bu Daris [(10)] , Tamama Jazim Nahar Alrwilay [(11)]

(1) Eastern Breeze Health Center,Ministry of Health, Saudi Arabia,
(2) Second Health Cluster – Eastern Breeze Health Center,Ministry of Health, Saudi Arabia,
(3) Health Monitoring Centres at King Abdulaziz International Airport,Ministry of Health, Saudi Arabia,
(4) Al-Ahsa Al-Omran Hospital,Ministry of Health, Saudi Arabia,
(5) Al Yamamah Hospital , Ministry of Health, Saudi Arabia,
(6) Bani Salem Health Center,Ministry of Health, Saudi Arabia,
(7) Al-Jawa Eye Health Center – Qassim,Ministry of Health, Saudi Arabia,
(8) Al Maarsh PHC – Hail Health Cluster,Ministry of Health, Saudi Arabia,
(9) Women's, Maternity and Children's Hospital, Arar,Ministry of Health, Saudi Arabia,
(10) Al-Jabr Kidney Center, Al-Ahsa,Ministry of Health, Saudi Arabia,
(11) King Abdulaziz Specialist Hospital, Sakaka – Heart Center,Ministry of Health, Saudi Arabia

Abstract

Background: *Mycoplasma pneumoniae* is a leading cause of atypical pneumonia, characterized by subacute onset, mild systemic symptoms, and diagnostic challenges due to its unique microbiologic properties. It accounts for a significant proportion of community-acquired respiratory infections and can present with extrapulmonary complications.

Aim: To review nursing assessment, evidence-based management, and infection prevention strategies for *M. pneumoniae* infection.

Methods: A comprehensive literature review was conducted, synthesizing epidemiologic data, pathophysiology, clinical presentation, diagnostic modalities, treatment protocols, and nursing interventions.

Results: *M. pneumoniae* infection often manifests with persistent dry cough, minimal chest findings, and normal leukocyte counts. Diagnosis relies on PCR and serology, as culture is impractical. Recommended treatment includes macrolides, doxycycline, or fluoroquinolones, with azithromycin commonly preferred. Supportive care and patient education are essential. Complications range from pulmonary (pleural effusion, ARDS) to systemic (neurologic, cardiac, dermatologic). Prognosis is generally favorable, though severe outcomes occur in children and high-risk groups. Preventive strategies emphasize respiratory hygiene, vaccination against other pathogens, and smoking cessation.

Conclusion: Effective management of *M. pneumoniae* requires early recognition, appropriate antibiotic selection, and robust nursing education to prevent transmission and complications. Interprofessional collaboration enhances outcomes, particularly in vulnerable populations.

Keywords: Mycoplasma pneumoniae, atypical pneumonia, nursing care, PCR diagnosis, macrolide resistance, infection prevention.

Introduction

Mycoplasma pneumonia is a bacterial pathogen capable of infecting humans and producing a spectrum of respiratory disease. Although it most frequently manifests as an upper respiratory tract infection, it may also involve the lower respiratory tract and cause pneumonia. In epidemiologic terms, it is recognized as one of the leading causes of atypical pneumonia in the United States, reflecting its common role in community-acquired respiratory illness and its characteristic clinical pattern of subacute onset and often less prominent consolidation findings when compared with typical bacterial pneumonias.[1][2][3] The organism's clinical importance is further underscored by the range of syndromes reported in association with Mycoplasma pneumoniae infection, extending beyond pulmonary disease. Numerous extrapulmonary manifestations have been described, involving multiple organ systems; however, despite the breadth of reported associations, a definitive causal relationship between M pneumoniae infection

*Corresponding author e-mail: Magalanazi@Moh.Gov.Sa (Maha Ghdaif Alanazi).
Receive Date: 25 November 2025, Revise Date: 20 December 2025, Accept Date: 22 December 2025

and many extrapulmonary conditions has not yet been conclusively established.[1][2][3] This uncertainty has significant implications for clinical interpretation, as it necessitates cautious attribution of systemic findings to M pneumoniae and supports the need for continued research to clarify mechanisms and strengthen causal inference. Historically, the clinical entity now commonly linked to M pneumoniae was first characterized before the pathogen itself was fully understood. Reimann provided an early description of this condition after observing a small series of seven patients who presented with pronounced constitutional symptoms, a clinical picture that did not align neatly with then-prevailing concepts of bacterial pneumonia. He introduced the term "primary atypical pneumonia" to distinguish this illness from pneumonias that typically presented with abrupt onset, high fever, and lobar consolidation.[1][2][3] This early characterization helped establish a clinical framework for recognizing atypical pneumonia as a distinct syndrome, one that would later be associated with organisms such as M pneumoniae. As understanding of atypical pathogens has advanced, Mycoplasma pneumonia has remained clinically relevant due to its prevalence, its variable presentation, and the diagnostic and therapeutic challenges it can pose in both outpatient and inpatient settings.[1][2][3]

Etiology

Mycoplasma species represent a distinctive group of bacteria characterized by their exceptionally small size and their capacity to survive independently in the natural environment. Within this genus, more than 120 species have been identified; however, only a limited subset has demonstrated relevance to human health. Approximately 13 Mycoplasma species have been isolated from humans, and among these, only four are recognized as established causes of human disease. Within clinical practice, *Mycoplasma pneumoniae* is the species most consistently and commonly associated with symptomatic infection in humans, particularly in the context of respiratory tract illness.[4] The microbiologic properties of *M pneumoniae* account for several of the diagnostic challenges that surround its identification. Structurally, the organism is described as a short rod that lacks a cell wall, a feature that has important laboratory and therapeutic implications. The absence of a cell wall means that *M pneumoniae* does not retain Gram stain characteristics in a way that allows visualization through routine Gram staining; consequently, it is typically not seen on standard microscopic examination of respiratory specimens.[4] This same structural feature also contributes to intrinsic resistance to antimicrobial agents that target cell wall synthesis, reinforcing the need for appropriate diagnostic suspicion and targeted therapy selection. From a culture standpoint, *M pneumoniae* can be isolated using specialized media supplemented with serum, reflecting its dependence on external lipid and growth factors. Nevertheless, the organism is considered fastidious, and its laboratory cultivation is not routinely pursued in most clinical microbiology settings.[4] Several practical constraints explain why routine culture is uncommon. First, *M pneumoniae* requires specific culture media that are not part of standard bacterial culture workflows, making routine implementation resource-intensive. Second, growth is notably slow, and extended incubation periods are often required before colonies can be detected, which limits the clinical usefulness of culture for timely decision-making in acute respiratory illness.[4] In addition, the organism may be shed from the respiratory tract for weeks following the acute phase of infection. As a result, even when isolation is achieved, the finding may not necessarily confirm that the organism is the cause of illness at that precise time, thereby reducing the specificity of culture for diagnosing acute infection.[4] These combined features—fastidious growth requirements, prolonged incubation, and extended post-infection shedding—help explain why *M pneumoniae* is not routinely cultured in clinical laboratories and why diagnosis often relies on alternative approaches rather than direct isolation.[4]



Fig. 1: Mycoplasma pneumonia.

Epidemiology

Mycoplasma pneumoniae is widely recognized as a frequent etiologic agent of community-acquired pneumonia and represents an important contributor to respiratory illness across a broad range of clinical severities. Transmission occurs primarily through person-to-person spread via respiratory droplets, particularly in settings characterized by close, sustained interpersonal contact.[5][4] This mode of spread explains the organism's propensity to circulate within households, schools, and other congregate environments, and it also underpins the occurrence of outbreaks in semi-closed communities. The incubation period is relatively prolonged compared with many other respiratory pathogens, typically ranging from approximately two to three weeks, which can complicate outbreak recognition and facilitate silent dissemination before cases are clinically apparent.[5][4] Seasonal patterns are observed, with

infections tending to occur more commonly during winter months, consistent with the broader epidemiology of many respiratory pathogens; however, transmission and disease can occur throughout the year.[5][4] In the United States, available estimates suggest that roughly 1% of the population becomes infected annually.[5][4] Importantly, this figure may underestimate the true incidence because *M pneumoniae* infection can be subclinical or manifest as mild upper respiratory tract illness that does not prompt medical evaluation or hospitalization. Consequently, a substantial proportion of infections may remain unrecognized, particularly in outpatient contexts where symptoms resemble other viral or atypical respiratory syndromes.[5][4] Epidemiologic observations also indicate that outbreaks are more likely in institutional or congregate settings where close contact is unavoidable and exposure is repetitive. Documented outbreaks have been reported among military recruits and within healthcare-related environments such as hospitals, nursing homes, and other long-term care facilities.[5][4] These settings combine multiple risk-enhancing factors, including shared airspace, frequent close interactions, and the presence of vulnerable individuals with comorbidities who may be more likely to develop clinically significant disease. Despite the relatively high frequency of infection, only a minority of infected individuals develop pneumonia; estimates suggest that approximately 5% to 10% of those infected progress to pneumonic illness.[5][4] Nonetheless, *M pneumoniae* remains clinically important because it can cause both upper and lower respiratory tract infections across all age groups, contributing to a substantial overall burden of respiratory disease even when pneumonia represents only a fraction of total infections.[5][4]

Pathophysiology

The pathophysiology of *Mycoplasma pneumoniae* infection is driven by a combination of direct microbial effects on the respiratory epithelium and an accompanying host immune response that may extend beyond the lungs. A central early event is adherence of the organism to epithelial cell membranes, particularly those lining the respiratory tract. This attachment is mediated by specialized adherence proteins that enable close, persistent contact with the host epithelium. Once anchored, *M pneumoniae* can exert cytotoxic effects through the generation of reactive oxygen species, including hydrogen peroxide and superoxide. These oxidant molecules injure epithelial cells and damage their associated cilia, thereby disrupting the mucociliary escalator that normally clears inhaled particles and microorganisms from the airways. Loss of epithelial integrity and impairment of ciliary function together contribute to airway irritation, increased susceptibility to secondary colonization, and the inflammatory milieu characteristic of atypical pneumonia [5]. In addition to oxidative injury, *M pneumoniae* displays motility features that facilitate persistence in the airway surface environment. The organism exhibits a distinctive gliding movement and possesses specialized tip organelles that support intimate attachment and mechanical migration along mucosal surfaces. These properties allow the bacterium to move between cilia and effectively "burrow" within the ciliated epithelial layer, promoting localized epithelial disruption. As infection progresses, the mechanical and biochemical insults can lead to sloughing of respiratory epithelial cells, further impairing barrier function and amplifying inflammatory signaling. Clinically, a prominent and often prolonged cough is a hallmark symptom, and this refractoriness has been attributed, at least in part, to inhibition of ciliary movement and the resulting accumulation of secretions and irritants within the airways. The persistent cough may therefore reflect both ongoing epithelial dysfunction and sustained airway inflammation, even when systemic symptoms appear modest [5].

The host immune response is a major determinant of disease expression and may also explain many extrapulmonary manifestations. *M pneumoniae* infection is associated with activation of inflammatory cytokines, which contribute to local pulmonary inflammation and can also have systemic effects. Moreover, antibodies generated against *M pneumoniae* antigens may display cross-reactivity with host tissues. Such antibodies can behave as autoantibodies when they recognize epitopes shared between bacterial components and human cells, including reported cross-reactivity with brain cells and red blood cells. This immune cross-reactivity provides a plausible mechanistic basis for certain neurologic and hematologic complications and highlights why extrapulmonary disease may occur even when respiratory involvement is mild. Consistent with these immunologic mechanisms, *M pneumoniae* has been associated with a range of extrapulmonary syndromes in addition to respiratory tract infections. Reported manifestations include immune thrombocytopenic purpura, acute hepatitis, autoimmune hemolytic anemia, arthritis, and transverse myelitis. These conditions likely arise through a combination of immune-mediated injury, inflammatory cytokine effects, and, in some cases, vascular or neurologic involvement triggered by the infection. Accordingly, *M pneumoniae* should be understood not only as a respiratory pathogen but also as an organism capable of provoking systemic immune phenomena that may complicate the clinical course and broaden the differential diagnosis in affected patients [5].

History and Physical

A substantial proportion of infections caused by *Mycoplasma pneumoniae* are clinically silent, and many affected individuals may remain asymptomatic

or experience symptoms so mild that medical attention is not sought. When illness is symptomatic, a characteristic clinical feature is the frequent discordance between the patient's subjective symptom burden and the relative paucity of objective abnormalities detected on physical examination. This clinicopathologic mismatch reflects the atypical nature of *M pneumoniae* respiratory disease, in which constitutional and upper airway complaints may be prominent while classic signs of lobar consolidation are often absent or delayed. The onset is typically insidious rather than abrupt, and patients commonly describe a gradual development of nonspecific systemic symptoms, including headache, malaise, and low-grade fever. These early manifestations may resemble viral respiratory syndromes, contributing to delayed presentation and diagnostic uncertainty in outpatient settings. As the clinical course evolves, a persistent, irritating cough often becomes the dominant respiratory complaint and may be the most consistent presenting feature. This cough is frequently described as nagging or refractory and can be disproportionate to auscultatory findings. Because coughing episodes may be prolonged and forceful, chest wall or substernal soreness is common and may reflect musculoskeletal strain rather than pleuritic inflammation. Wheezing may occur, particularly in individuals with reactive airway tendencies, and can lead to misclassification as asthma exacerbation or acute bronchitis. Additional respiratory or otolaryngologic symptoms may include pharyngitis, rhinorrhea, and ear pain, underscoring that *M pneumoniae* can present with mixed upper and lower respiratory tract involvement. In patients who progress to pneumonia, pleural effusion has been reported in approximately 15% to 20% of cases and may be a marker of greater disease severity, with potential implications for increased morbidity and mortality. Although most pneumonia cases associated with *M pneumoniae* are mild and self-limited, clinicians should remain vigilant for less common scenarios in which the disease course becomes fulminant, particularly in vulnerable populations or in the presence of significant comorbidity [6].

Extrapulmonary manifestations, although relatively infrequent, may provide diagnostically useful clues and can broaden the clinical picture beyond a straightforward respiratory illness. Such features may include evidence of hemolysis, dermatologic eruptions, arthralgia, gastrointestinal symptoms, and signs suggestive of cardiac involvement. These extrapulmonary findings are generally reported in fewer than 5% to 10% of patients but are clinically important because they may drive complications and prompt alternative diagnostic pathways. Hemolysis is classically linked to IgM-mediated cold agglutinin activity, which can produce red blood cell agglutination and immune hemolytic phenomena. Cardiac involvement, while uncommon, may present with conduction abnormalities detectable on electrocardiography, symptoms or signs of congestive heart failure, and chest pain, emphasizing the need for careful cardiovascular assessment when systemic symptoms appear disproportionate or when patients describe cardiopulmonary complaints beyond cough and mild dyspnea. On physical examination, findings may be subtle or even normal, including in patients with radiographic evidence of pneumonia. Chest auscultation can be unremarkable early in the illness, and classic focal findings may be absent. As disease progresses, scattered rales and wheezes may become evident, often reflecting diffuse airway and interstitial involvement rather than localized alveolar consolidation. Examination of the upper airway may reveal mild erythema of the posterior pharynx, and sinus tenderness can be present, consistent with associated upper respiratory tract inflammation. Dermatologic inspection may identify a mild erythematous maculopapular or vesicular rash, which, although nonspecific, can support consideration of atypical infection when seen in conjunction with respiratory symptoms. Otoscopic examination may reveal bullous myringitis in some cases, characterized by vesicles or bullae on the tympanic membrane, and this finding—when present—can be a helpful clinical association. Overall, the history and physical examination in *M pneumoniae* infection demand careful synthesis, as the diagnosis is often suggested by the pattern of gradual onset, persistent cough, minimal early chest findings, and occasional extrapulmonary indicators rather than by a single definitive clinical sign [6].



Fig. 2: Symptoms of Mycoplasma pneumoniae.

Evaluation

The clinical evaluation of *Mycoplasma pneumoniae* infection is often challenging because neither the symptom profile nor radiographic findings are pathognomonic, and the disease may closely resemble other causes of atypical pneumonia. In routine practice, no single clinical sign, laboratory pattern, or imaging feature reliably distinguishes mycoplasma pneumonia from pneumonias caused by organisms such as *Chlamydophila pneumoniae*, *Legionella* species, or a variety of respiratory viruses. Nevertheless, certain tendencies can support clinical

suspicion. Patients with *M pneumoniae* infection frequently demonstrate a more gradual, insidious onset of symptoms, may exhibit multisystem involvement, and often maintain a normal white blood cell count, features that collectively align with the "atypical" clinical phenotype rather than the abrupt, highly inflammatory profile of typical bacterial pneumonia. In many settings, affected patients initially present and are managed in outpatient care. Because empiric therapy for community-acquired pneumonia is commonly effective, microbial confirmation is not routinely pursued for outpatients, particularly when illness is mild and uncomplicated. This pragmatic approach is shaped by considerations of cost, turnaround time, and limited impact of confirmatory testing on immediate management. However, microbiologic confirmation may become important in cases with more severe disease, treatment failure, high-risk comorbidity, epidemiologic cluster suspicion, or when rapid differentiation affects isolation or therapeutic decisions. When diagnostic testing is available and clinically indicated, polymerase chain reaction (PCR) offers a rapid and sensitive method and is generally regarded as the test of choice due to its ability to detect pathogen genetic material directly from respiratory specimens.[6][7] In circumstances where rapid decision-making is necessary and molecular testing is not readily accessible, measurement of cold agglutinins can sometimes provide supportive evidence for a presumptive diagnosis, although it cannot be considered definitive.[6][7] Standard microbiologic approaches used for typical bacterial pneumonia are not useful for *M pneumoniae* due to the organism's distinctive structural and growth characteristics. Because it lacks a cell wall, *M pneumoniae* is not reliably visualized on Gram stain, and conventional bacterial culture techniques are poorly suited to its recovery. Moreover, the organism is fastidious and requires specialized culture media, and growth is slow, typically requiring extended incubation—on the order of 7 to 21 days—before yielding detectable results.[6][7] These limitations reduce the clinical utility of culture for acute decision-making and explain why culture is rarely used in routine evaluation.

Serologic testing provides an alternative diagnostic pathway and may demonstrate acceptable sensitivity and specificity in appropriate contexts. Assays such as complement fixation, enzyme-linked immunoassay, immunochromatography, and hemagglutination have been used to support diagnosis, particularly when PCR is unavailable or when retrospective confirmation is required. Diagnostic interpretation often relies on either a significant change in antibody titers over time—such as a four-fold rise or fall in paired sera—or a single elevated titer above a specified threshold (for example, greater than 1:32), which may be considered consistent with *M pneumoniae* infection. While serology can be valuable, it must be interpreted carefully in relation to symptom timing, because antibody responses may lag behind clinical onset and may persist after recovery. Hematologic findings can provide additional supportive clues but are neither universally present nor specific. Hemolysis has been reported in many patients with mycoplasma pneumonia and may be reflected by a positive Coombs test and an elevated reticulocyte count, findings consistent with immune-mediated red cell destruction. Cold agglutinin titers are elevated in more than half of patients with mycoplasma disease, reinforcing their role as a supportive marker.[6][7] However, cold agglutinins are not specific to *M pneumoniae* and may also be observed in viral pneumonia and in infectious mononucleosis due to Epstein–Barr virus or cytomegalovirus, limiting their diagnostic specificity. Similarly, although leukocyte counts are often normal—reported in approximately 75% to 90% of cases—this pattern is not exclusive to mycoplasma infection and may be seen in other atypical or viral respiratory illnesses. Radiographic evaluation is likewise supportive rather than definitive. The most frequently described chest radiograph patterns include reticulonodular infiltrates or patchy areas of consolidation, which may be unilateral or bilateral and are often more prominent in the lower lobes.[8][9] These findings are consistent with interstitial and peribronchial inflammation typical of atypical pneumonia, yet they overlap significantly with other infectious and noninfectious pulmonary processes. Therefore, imaging must be interpreted alongside clinical trajectory, oxygenation status, and laboratory data. Additional emerging biomarkers have been explored; for example, eosinophil cationic protein has been observed to be elevated in individuals with mycoplasma infection and asthma and has been hypothesized to contribute to airway epithelial injury and bronchial smooth muscle hypersensitivity. However, evidence remains insufficient for its routine diagnostic application, and further studies are required before it can be adopted as a universal diagnostic marker.[10]

Treatment / Management

Clinical suspicion for *Mycoplasma pneumoniae* pneumonia commonly arises from a characteristic pattern in which symptoms develop gradually, constitutional complaints may be prominent, and objective findings—particularly leukocytosis—are often absent. When this subacute presentation is accompanied by extrapulmonary manifestations, the overall profile becomes increasingly suggestive of an atypical pneumonia syndrome. In practice, however, distinguishing mycoplasma pneumonia from other atypical pathogens based on clinical features alone remains difficult, and treatment decisions are frequently made

empirically. This approach is especially relevant because most patients with *M pneumoniae* respiratory infection present and are managed in outpatient settings, where the illness is often mild to moderate and where confirmatory microbiologic testing is not routinely pursued. It is also common for individuals to experience a period of symptomatic self-management before seeking medical care, which can delay both clinical assessment and initiation of antibiotic therapy. As a result, clinicians must integrate the temporal evolution of symptoms with epidemiologic context and the presence of multisystem features when deciding whether to initiate empiric therapy directed at atypical organisms. When antimicrobial treatment is indicated, recommended options for *M pneumoniae* include macrolides, doxycycline, or fluoroquinolones, reflecting the organism's lack of a cell wall and the consequent ineffectiveness of beta-lactam antibiotics that target cell wall synthesis. Among these agents, azithromycin is commonly selected because of its favorable dosing convenience, tolerability, and established effectiveness in atypical community-acquired pneumonia. A frequently used regimen is a five-day course, administered as 500 mg on the first day followed by 250 mg daily for the subsequent four days.[11][12] Alternative regimens may be chosen on the basis of patient-specific factors such as allergy history, pregnancy status, potential drug–drug interactions, and local prescribing practices. In patients for whom macrolides are unsuitable or in whom an alternative is clinically preferred, doxycycline or a fluoroquinolone may be used. In these cases, treatment duration is generally longer, commonly ranging from seven to fourteen days, reflecting differences in pharmacokinetics, clinical protocols, and the need to ensure adequate pathogen suppression in a syndrome that can be protracted.[11][12]

An increasingly important consideration in contemporary management is the emergence of macrolide resistance. Although macrolides have historically been reliable first-line agents for mycoplasma infections, resistant strains have become more prevalent in various regions, creating the potential for clinical non-response. In a patient receiving macrolide therapy who fails to demonstrate clinical improvement—particularly if fever persists, cough worsens, or functional status declines—clinicians should consider alternative explanations such as incorrect diagnosis, complications, or co-infection, while also recognizing macrolide resistance as a plausible contributor. In such circumstances, switching to an alternative antibiotic class, such as doxycycline or a fluoroquinolone, may be appropriate to achieve effective coverage. This stepwise approach aligns with rational antimicrobial stewardship principles, as it preserves macrolides as initial therapy when likely to be effective but encourages prompt modification when response is inadequate. Management is not exclusively pharmacologic. Because many cases are mild and self-limited, supportive care remains central, particularly early in the illness or for patients with minimal physiologic compromise. Symptom-directed measures may include hydration, antipyretics, and interventions to reduce cough-related discomfort, as persistent coughing can contribute to chest soreness and fatigue. Clinical reassessment is important if symptoms progress, if oxygenation deteriorates, or if extrapulmonary manifestations develop, as these features may indicate more severe disease or systemic immune-mediated complications. The decision to treat with antibiotics should also account for severity, comorbidities, and the risk of complications, recognizing that the goals of therapy include symptom reduction, limitation of disease duration, prevention of complications, and reduction of transmission in high-risk environments. With respect to public health and exposure management, routine antibiotic prophylaxis for contacts exposed to *M pneumoniae* is generally not required. This reflects the fact that many infections are mild, self-limited, and widely distributed in the community, and indiscriminate prophylaxis would increase antimicrobial exposure without clear net benefit. An exception is made for individuals at increased risk of serious mycoplasmal infection, such as patients with sickle cell disease or antibody deficiency, in whom infection may lead to more severe clinical consequences. In these selected high-risk groups, prophylaxis may be considered, and when used, doxycycline or macrolides are typical agents.[11][12] Even in these cases, prophylactic decisions should be individualized, balancing potential benefits against adverse effects, contraindications, and the broader imperative to minimize unnecessary antibiotic use.

Differential Diagnosis

The differential diagnosis of *Mycoplasma pneumoniae* infection should be approached systematically, because the clinical and radiographic profile of atypical pneumonia is inherently nonspecific and overlaps substantially with infectious and noninfectious pulmonary syndromes. Several epidemiologic and clinical considerations can raise or lower the probability of mycoplasma pneumonia, particularly in ambulatory settings where most cases are initially evaluated. *M pneumoniae* is a frequent cause of community-acquired pneumonia among otherwise healthy individuals younger than 40 years, and its prevalence in this age group often reflects patterns of exposure within schools, workplaces, and social environments where close contact facilitates respiratory droplet transmission. Outbreaks have been described as occurring commonly in late summer and early fall, and infection rates tend to rise in populations living in close quarters—such as prisoners and military personnel—where repeated exposure and constrained living environments increase transmission efficiency. A distinguishing

epidemiologic feature is the relatively prolonged incubation period, typically 14 to 21 days, which contrasts with the shorter incubation windows associated with many viral respiratory infections and can complicate outbreak tracing and temporal linkage between exposure and symptom onset [11][12]. From a clinical standpoint, the diagnostic impression is often informed by the characteristic subacute trajectory and cough phenotype. In suspected mycoplasma pneumonia, cough may be prominent yet often described as nonproductive or minimally productive, and the relative absence of a "wet" cough can be viewed as a supportive feature, especially early in the disease course. However, this observation must be interpreted cautiously, because sputum production can vary with disease stage, hydration status, coexisting airway disease, and secondary bacterial infection. Consequently, while cough quality can contribute to clinical suspicion, it cannot reliably exclude alternative etiologies. Given these uncertainties, clinicians must maintain a broad differential diagnosis that includes pathogens and syndromes that can mimic atypical pneumonia in presentation, radiographic appearance, and laboratory profile.

Aspiration pneumonitis and aspiration pneumonia represent important considerations, particularly in patients with impaired airway protection, altered mental status, dysphagia, gastroesophageal reflux, or recent vomiting. Aspiration syndromes may produce acute respiratory symptoms and radiographic infiltrates that can resemble infectious pneumonia; however, aspiration pneumonitis often follows a more abrupt onset linked to a clear aspiration event, whereas aspiration pneumonia may evolve more insidiously. Bacterial pneumonia must also remain a central alternative, especially when fever is higher, leukocytosis is present, or lobar consolidation is evident. Typical bacterial pathogens can produce productive cough, pleuritic chest pain, and systemic toxicity, but mild cases may still resemble atypical syndromes early on [11][12]. Other atypical pathogens frequently overlap with *M pneumoniae* clinically. *Chlamydia pneumoniae* can cause subacute community-acquired pneumonia with pharyngitis and prolonged cough, often making differentiation from mycoplasma difficult without targeted testing. *Legionella pneumophila* is another key differential diagnosis, particularly in patients with severe pneumonia, hyponatremia, gastrointestinal symptoms, or relevant exposure histories (for example, contaminated water sources), although mild cases may not display classic features. *Coxiella burnetii* infection, the cause of Q fever, should be considered when epidemiologic exposure suggests risk—such as contact with farm animals or parturient livestock—or when pneumonia coexists with systemic features such as hepatitis. Because Q fever may present with nonspecific respiratory symptoms and systemic illness, it can be misinterpreted as an atypical community-acquired pneumonia syndrome unless exposure history is carefully elicited. Complicated pleuropulmonary infections should also be considered in patients with persistent symptoms, pleuritic pain, or poor response to empiric therapy.

Empyema may complicate bacterial pneumonia and can present with ongoing fever and respiratory compromise despite antibiotics, while lung abscess should be considered when there is a history of aspiration risk, fetid sputum, or cavitary radiographic lesions. These complications often require different management strategies, including drainage procedures or prolonged antibiotic courses, and misclassification as uncomplicated atypical pneumonia can delay definitive care. Viral pneumonia remains a broad and clinically important category in the differential diagnosis, as many respiratory viruses can present with fever, cough, dyspnea, and patchy infiltrates. Although viral illnesses often have shorter incubation periods than mycoplasma, this distinction is not absolute, and clinical overlap is considerable. In pediatric populations, pneumonia etiologies and presentations can differ from adults, and pediatric pneumonia should be considered as a category that includes viral causes, typical bacteria, and atypical pathogens such as *M pneumoniae*, particularly in school-aged children and adolescents. Ultimately, accurate differentiation requires synthesis of age, exposure setting, incubation characteristics, cough quality, systemic features, radiographic patterns, and—when indicated—microbiologic testing. This integrated approach helps ensure that mycoplasma pneumonia remains appropriately considered without prematurely excluding other causes of community-acquired pneumonia that may demand distinct therapeutic or infection-control responses [11][12].

Prognosis

The overall prognosis of *Mycoplasma pneumoniae* infection is generally favorable, particularly when the condition is recognized early and managed appropriately. In most patients who receive timely therapy, clinical outcomes are excellent, and full recovery is expected. Symptomatic improvement commonly occurs within days, and the manifestations of pneumonia—such as fever, malaise, and cough—often abate without progression to serious complications. This typically benign trajectory is consistent with the observation that many cases are mild, self-limited, and managed successfully in outpatient settings, especially among otherwise healthy adolescents and adults. Nevertheless, prognosis is not uniformly benign across all populations. Young children may experience a more severe clinical course, including significant lower respiratory tract involvement and, in some cases, severe pneumonia. This increased

vulnerability likely reflects developmental differences in immune response, airway caliber, and physiologic reserve, which can magnify the impact of airway inflammation and impaired gas exchange. Similarly, individuals with underlying hematologic conditions, particularly sickle cell anemia, represent a clinically important high-risk group. In this population, *M pneumoniae* infection has been associated with acute chest syndrome, a serious complication characterized by new pulmonary infiltrates and respiratory symptoms that can rapidly progress and requires urgent clinical attention. The association with acute chest syndrome carries meaningful prognostic implications, as it may increase hospitalization risk, necessitate intensive supportive care, and contribute to significant morbidity. An additional prognostic consideration is the nature of post-infectious immunity. Immunity following *M pneumoniae* infection is described as short-lived, indicating that prior infection does not confer durable long-term protection. Consequently, reinfection is possible, and population-level susceptibility can persist even in communities with prior circulation. This limited duration of protective immunity helps explain why *M pneumoniae* continues to cause recurrent outbreaks and why individuals may experience more than one episode over time. Overall, while most patients recover fully and rapidly, clinicians should maintain heightened vigilance for severe disease in pediatric patients and for high-risk complications in individuals with sickle cell disease, while also recognizing that recurrence remains possible due to transient immunity [12].

Complications

Although *Mycoplasma pneumoniae* infection is frequently mild and self-limited, it is important to recognize that clinically meaningful complications can occur, particularly at the extremes of age and among individuals with reduced physiologic reserve. Children and older adults may be more susceptible to severe pulmonary involvement because airway caliber, baseline cardiopulmonary function, and immune responsiveness influence the capacity to compensate for inflammation and impaired gas exchange. In addition, complications may arise either from progressive respiratory tract disease itself or from immune-mediated phenomena triggered by the host response to infection. Consequently, an apparently benign presentation can, in a subset of patients, evolve into significant morbidity requiring hospitalization, escalation of respiratory support, or multidisciplinary evaluation. Pulmonary complications span a continuum from localized parenchymal disease to diffuse inflammatory lung injury. In some patients, infection may progress beyond the typical patchy infiltrates of atypical pneumonia to produce lobar consolidation, thereby resembling typical bacterial pneumonia radiographically and clinically. Severe inflammatory injury can culminate in necrotizing pneumonitis, characterized by tissue destruction and potential cavitation, and in rare cases may be complicated by lung abscess formation. These entities are clinically important because they are associated with prolonged fever, persistent respiratory symptoms, and slower radiographic resolution, and they may necessitate broader diagnostic consideration for co-infection, aspiration, or alternative pathogens. Pleural involvement is also documented. Pleural effusion is reported in approximately 15% to 20% of cases of mycoplasma pneumonia and may signal greater disease burden and increased risk of clinical deterioration. Progression from effusion to empyema is considered rare but represents a high-stakes complication because it may require drainage procedures in addition to antimicrobial therapy. More diffuse airway and parenchymal sequelae can also occur. Bronchiolitis obliterans, although uncommon, is a notable long-term complication characterized by inflammatory and fibrotic narrowing of small airways, which can lead to persistent airflow limitation and chronic respiratory symptoms. At the severe end of the spectrum, respiratory failure may develop, reflecting inability to maintain adequate oxygenation and ventilation, and acute respiratory distress syndrome (ARDS) may occur, representing diffuse alveolar damage and severe hypoxemic respiratory failure that typically requires intensive care support. These pulmonary complications collectively emphasize that, while most cases are mild, clinicians must monitor for escalation in oxygen requirement, worsening work of breathing, and radiographic progression, especially in higher-risk patients [12].

A distinctive and clinically significant aspect of *M pneumoniae* infection is its association with extrapulmonary complications, many of which appear to be mediated by immune mechanisms rather than by direct tissue invasion. These systemic manifestations may be triggered by inflammatory cytokine activation, immune complex formation, and antibody cross-reactivity with host antigens. Cardiac complications, though uncommon, can be serious and include conduction abnormalities, atrioventricular blocks, and rhythm disturbances. Reports have described pericarditis and congestive heart failure even in younger individuals, highlighting that cardiac involvement is not confined to older adults with preexisting cardiovascular disease. When patients develop chest pain, palpitations, syncope, or unexplained hemodynamic instability in the setting of recent respiratory infection, clinicians should consider possible cardiac involvement and evaluate appropriately. Neurologic complications are rare but particularly important due to their potential severity and long-term consequences. Documented manifestations include encephalitis, transverse myelitis, aseptic meningitis, and cerebellar ataxia. These central nervous system complications are reported more commonly in children, which may

reflect age-related immune response patterns or differences in susceptibility. Because neurologic involvement may develop after respiratory symptoms begin or even as respiratory symptoms improve, clinicians should maintain vigilance for new neurologic deficits, altered mental status, seizures, gait disturbance, or focal weakness following suspected mycoplasma infection [12].

Hematologic complications are also well recognized. The most characteristic is mild hemolytic anemia arising from antibody cross-reactivity, in which antibodies generated against *M pneumoniae* antigens bind to red blood cell surfaces, leading to immune-mediated hemolysis. Although hemolysis is often mild, it can contribute to fatigue, pallor, or jaundice and may be clinically relevant in patients with baseline anemia or hemoglobinopathies. Dermatologic involvement is relatively frequent in comparison with other extrapulmonary manifestations and may include urticaria, erythema nodosum, and, in severe cases, Stevens–Johnson syndrome. Skin lesions have been described in approximately one-third of patients, making cutaneous findings a potentially helpful diagnostic clue when present alongside respiratory symptoms. Because Stevens–Johnson syndrome is a medical emergency, any mucocutaneous blistering or significant skin detachment warrants urgent evaluation. Musculoskeletal symptoms such as myalgia and arthralgia may occur and can reflect systemic inflammation rather than localized infection. Septic arthritis is very rare, but its mention underscores the need to distinguish inflammatory joint symptoms from true joint infection when patients present with focal joint swelling, warmth, or severe pain. Rare cases of rhabdomyolysis have also been reported, and while uncommon, this complication carries risk of acute kidney injury and requires prompt recognition through clinical suspicion and laboratory testing. Gastrointestinal complications, including pancreatitis and hepatitis, have been described and are thought to be linked to circulating immunoglobulin M antibodies and immune-mediated injury. These manifestations may present with abdominal pain, nausea, vomiting, or abnormal liver enzymes and may complicate management if they limit oral intake or affect medication tolerability. Ophthalmologic complications further broaden the systemic spectrum and can include conjunctivitis, optic papillitis, anterior uveitis, and cranial neuropathies. These findings may present with eye redness, pain, photophobia, or visual changes and can require specialist assessment to prevent lasting impairment. Renal involvement is rare but has been reported in the form of glomerulonephritis, potentially mediated by immune complex deposition within the glomeruli. When present, it may manifest as hematuria, proteinuria, edema, or renal function decline. Overall, the complication profile of *M pneumoniae* underscores that, while typically benign, the infection can provoke significant pulmonary and systemic sequelae through combined infectious and immune-mediated pathways, necessitating careful monitoring and prompt escalation of care when warning signs emerge [12].

Patient Education

Effective patient education for *Mycoplasma pneumoniae* infection should emphasize two parallel goals: reducing transmission risk and strengthening individual resilience against respiratory illness and its complications. Patients should receive clear counseling on infection prevention measures, particularly because mycoplasma spreads primarily through respiratory droplets during close contact. Practical guidance includes consistent hand hygiene, covering the mouth and nose when coughing or sneezing, disposing of tissues appropriately, and avoiding close proximity to others while symptomatic. Patients should be advised to limit attendance at school, work, or crowded gatherings during periods of active coughing and fever, especially when vulnerable individuals may be present. Reinforcing these behaviors is clinically important because even mild cases can contribute to household and community transmission, and the organism's prolonged incubation period can allow spread before a clear pattern is recognized. Preventive counseling should also extend beyond mycoplasma-specific measures to include broader respiratory health strategies that reduce the likelihood of secondary infections and severe disease. Patients should be encouraged to remain up to date with recommended immunizations, including the pneumococcal vaccine and the annual influenza vaccine. While these vaccines do not prevent *M pneumoniae* infection directly, they can reduce the incidence of other respiratory infections and help prevent serious complications, including bacterial pneumonia following viral illness. Influenza prevention is particularly relevant because influenza can predispose patients to secondary bacterial pneumonia and can exacerbate chronic cardiopulmonary conditions, thereby amplifying overall risk in respiratory illness seasons. Education should be individualized to age, comorbidities, and national immunization schedules, and should include information on where and how to obtain vaccination. Smoking cessation counseling is another essential component. Patients who smoke should receive strong, supportive guidance to stop, as smoking impairs mucociliary clearance, damages airway epithelium, and increases vulnerability to respiratory infections and pneumonia. In addition to brief cessation advice, clinicians and nurses should offer practical resources, including referral to cessation programs, behavioral support, and pharmacologic aids when appropriate. Emphasizing the direct link

between smoking and respiratory compromise can improve motivation, while compassionate framing helps sustain engagement. Finally, education should address underlying chronic illnesses that increase pneumonia risk or worsen outcomes. Optimizing conditions such as asthma, diabetes, and congestive heart failure can reduce susceptibility to infection, improve physiologic reserve, and shorten recovery time. Patients should be encouraged to adhere to prescribed therapies, attend follow-up visits, and seek care promptly if respiratory symptoms worsen, fever persists, or new systemic symptoms develop [13].

Other Issues

Several clinical "pearls" are useful for framing the prevention and management of *Mycoplasma pneumoniae* in a professional nursing and clinical context. First, although vaccination is a cornerstone of respiratory infection prevention, there are currently no vaccines available for *M pneumoniae*. Consequently, primary prevention relies on general respiratory hygiene, minimizing exposure during outbreaks, and reinforcing infection-control measures in both community and healthcare settings. In closed or semi-closed environments—such as military training facilities—research has explored azithromycin prophylaxis as a strategy to reduce outbreak impact. However, despite investigational interest, there are no established recommendations supporting routine prophylaxis practices in such settings at present. This highlights a recurring challenge in infectious disease control: promising approaches may lack sufficient evidence for broad implementation, particularly when concerns about antimicrobial resistance and population-level stewardship are considered. In hospitalized patients, infection-control practice is especially important. Individuals admitted with *M pneumoniae* infection should be placed on droplet precautions for the duration of illness to reduce nosocomial transmission. This includes appropriate masking, patient placement decisions when feasible, and adherence to institutional protocols for personal protective equipment and hand hygiene. Clinical recognition also benefits from awareness of typical presentation patterns. *M pneumoniae* is a common cause of pneumonia, often preceded by prodromal symptoms such as headache and fever, followed by the development of a persistent dry cough. Importantly, infection is frequently subclinical or minimally symptomatic and may therefore be underdiagnosed, particularly because there is no single bedside feature that definitively establishes the diagnosis. Imaging does not always provide clarity; chest radiographs may fail to demonstrate an obvious infiltrate even when pneumonia is present, reinforcing the need for clinical synthesis rather than reliance on radiography alone. Management is generally antibiotic-based, with azithromycin commonly used as first-line therapy in many settings. Vigilance is required for vulnerable groups, including children, older adults, and individuals with sickle cell disease, who are more likely to experience complications and may require closer monitoring or earlier escalation of care. Optimizing outcomes depends on effective interprofessional collaboration. *Mycoplasma pneumonia* is frequently first encountered by primary care providers, nurse practitioners, emergency department physicians, and internists, making it a condition that traverses multiple care environments. Because rapid definitive testing is often unavailable, many patients are treated empirically, and most experience an uneventful recovery. Nevertheless, a subset may develop clinically significant complications such as parapneumonic effusion, otitis media, lung abscess, or empyema, which require timely recognition and referral to appropriate specialties for advanced evaluation and management. Nurses play a central role in early detection through monitoring symptom progression, oxygenation status, hydration, and clinical stability, and through ensuring continuity of patient education and follow-up planning. Pharmacists contribute by supporting appropriate antibiotic selection, dosing, interaction checks, and stewardship practices. In immunocompromised individuals and transplant recipients, the threshold for specialist input should be lower, and an infectious disease consultation is recommended to ensure comprehensive evaluation and tailored management.[13]

Conclusion:

Mycoplasma pneumoniae remains a clinically significant pathogen due to its prevalence, diagnostic complexity, and potential for systemic complications. Although most cases are mild and self-limiting, the infection can progress to severe pneumonia or trigger immune-mediated extrapulmonary syndromes, particularly in children and individuals with comorbidities such as sickle cell disease. Timely recognition and evidence-based management are critical to reducing morbidity. Empiric antibiotic therapy with macrolides, doxycycline, or fluoroquinolones remains the cornerstone of treatment, but emerging macrolide resistance underscores the need for vigilant monitoring and alternative regimens when clinical response is inadequate. Supportive care, including hydration and symptom relief, complements pharmacologic therapy. From a nursing perspective, patient education is pivotal. Counseling on respiratory hygiene, vaccination, and smoking cessation reduces transmission and strengthens overall respiratory health. Infection-control measures, especially droplet precautions in healthcare settings, are essential to prevent outbreaks. Interprofessional collaboration among nurses, physicians, and pharmacists ensures optimal antibiotic stewardship and continuity of care. Despite the generally favorable prognosis, clinicians must remain alert for complications such as pleural effusion, neurologic involvement, and dermatologic reactions, which may

necessitate specialized interventions. Ultimately, a proactive, multidisciplinary approach combining clinical vigilance, patient education, and preventive strategies offers the best pathway to improved outcomes in *M. pneumoniae* infection.

References:

[1] Cai ZH, Dai YY, Huang LY, Zhang WS, Guo XG. Diagnosis of mycoplasma pneumoniae by loop-mediated isothermal amplification: systematic review and meta-analysis. BMC infectious diseases. 2019 Feb 19:19(1):173. doi: 10.1186/s12879-019-3799-4.

[2] Lanao AE, Chakraborty RK, Pearson-Shaver AL. Mycoplasma Infections. StatPearls. 2025 Jan

[3] Tao Y, Shu J, Chen J, Wu Y, He Y. A concise review of vaccines against Mycoplasma hyopneumoniae. Research in veterinary science. 2019 Apr:123():144-152. doi: 10.1016/j.rvsc.2019.01.007.

[4] Rhim JW, Kang HM, Yang EA, Lee KY. Epidemiological relationship between Mycoplasma pneumoniae pneumonia and recurrent wheezing episode in children: an observational study at a single hospital in Korea. BMJ open. 2019 Apr 11:9(4):e026461. doi: 10.1136/bmjopen-2018-026461.

[5] Leung AKC, Wong AHC, Hon KL. Community-Acquired Pneumonia in Children. Recent patents on inflammation & allergy drug discovery. 2018:12(2):136-144. doi: 10.2174/1872213X12666180621163821.

[6] Qu J, Yang C, Bao F, Chen S, Gu L, Cao B. Epidemiological characterization of respiratory tract infections caused by Mycoplasma pneumoniae during epidemic and post-epidemic periods in North China, from 2011 to 2016. BMC infectious diseases. 2018 Jul 17:18(1):335. doi: 10.1186/s12879-018-3250-2.

[7] Bajantri B, Venkatram S, Diaz-Fuentes G. Mycoplasma pneumoniae: A Potentially Severe Infection. Journal of clinical medicine research. 2018 Jul:10(7):535-544. doi: 10.14740/jocmr3421w.

[8] Draenert R, Jung J, Seybold U, Bogner J. [Atypical pneumonia - important facts for the general practitioner]. MMW Fortschritte der Medizin. 2018 May:160(10):41-44. doi: 10.1007/s15006-018-0581-2.

[9] Kumar S. Mycoplasma pneumoniae: A significant but underrated pathogen in paediatric community-acquired lower respiratory tract infections. The Indian journal of medical research. 2018 Jan:147(1):23-31. doi: 10.4103/ijmr.IJMR_1582_16.

[10] Zhu YG, Tang XD, Lu YT, Zhang J, Qu JM. Contemporary Situation of Community-acquired Pneumonia in China: A Systematic Review. Journal of translational internal medicine. 2018 Mar:6(1):26-31. doi: 10.2478/jtim-2018-0006.

[11] Saraya T. Mycoplasma pneumoniae infection: Basics. Journal of general and family medicine. 2017 Jun:18(3):118-125. doi: 10.1002/jgf2.15.

[12] Wen Z, Wei J, Xue H, Chen Y, Melnick D, Gonzalez J, Hackett J, Li X, Cao Z. Epidemiology, microbiology, and treatment patterns of pediatric patients hospitalized with pneumonia at two hospitals in China: a patient chart review study. Therapeutics and clinical risk management. 2018:14():501-510. doi: 10.2147/TCRM.S143266.

[13] Yang TI, Chang TH, Lu CY, Chen JM, Lee PI, Huang LM, Chang LY. Mycoplasma pneumoniae in pediatric patients: Do macrolide-resistance and/or delayed treatment matter? Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2019 Apr:52(2):329-335. doi: 10.1016/j.jmii.2018.09.009.